Axon Announces Collaboration Agreement with Lundbeck on Axon's IPR

[Groningen, NL. Sept, 2004] Axon Biochemicals BV, The Netherlands (refer to Axon) and H. Lundbeck A/S, Denmark (refer to Lundbeck) have signed a collaboration agreement giving Lundbeck access to Axon's IPR on dopaminergic compounds with potential in the treatment of CNS disorders.

Axon is a small medicinal chemistry company with a unique expertise within the dopaminergic field. Axon has, in collaboration with the University of Groningen , developed a new innovative pro-drug concept for oral delivery of dopamine agonists in vivo.

"Lundbeck is committed to staying in the forefront of CNS drug discovery and by entering into this agreement we expand our knowledge base within one of our key areas of research, namely Parkinson's disease." said Dr. Peter Høngaard Andersen, Head of Research at Lundbeck.

"Lundbeck is a well-known CNS company with an impressive in depth knowledge on disease biology and medicinal chemistry within monoaminergic targets. Thus, we see Lundbeck as the perfect match for us on this matter" said Professor Håkan Wikström, co-owner of Axon.

Axon is currently acting and expanding its services and research capacities as a contract research organization in medicinal chemistry field.

About Axon

Axon is a medicinal chemistry company, incorporated in the Netherlands in 1999. Axon conducts research in developing novel drug candidates in the CNS field and has invested for self-owned intellectual properties such as patents at national phase. Together with EU, government institutions, and pharmaceutical companies, Axon is now actively involved in several drug discovery programs from pre-clinic to Phase I. Axon is also an independent contract research organization providing high quality services in medicinal chemistry research. The company is specifically involved in rapid synthesis of drug standards and in contract research on drug design and synthesis. The company, with its experienced medicinal chemists in front-line drug research, offers the power of outsourcing research to the pharmaceutical companies in the world.